Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
about
ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementSignatures of breast cancer metastasis at a glanceHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenBuilding the evidence base for decision making in cancer genomic medicine using comparative effectiveness researchGood practice guidelines for biomarker discovery from array data: a case study for breast cancer prognosis.Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis.Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer.Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.Tumor gene expression profiling in women with breast cancer. Test category: prognostic.Genome-based risk prediction for early stage breast cancer.The epidermal growth factor receptor family in breast cancer.New insight into Ki67 expression at the invasive front in breast cancer.The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?Review of the clinical studies using the 21-gene assay.Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancerGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancerBarriers to the use of personalized medicine in breast cancer.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patientsGene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Cellular iron metabolism in prognosis and therapy of breast cancer.A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimensImproving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.Gene expression profiling for breast cancer prognosis in Chinese populations.
P2860
Q24810389-CE14D921-6E21-4936-8152-8AACF3727C94Q27020973-58F825E9-0B6C-4875-8112-A4DCB5A68DD1Q28071451-7ADBC9CC-5C2A-4F31-81AA-17D7C6B3AEAFQ28077637-FED798EC-2117-4B40-BABF-8E85C74AEBCEQ30419845-93C2EB5C-C6CE-4980-BC0D-CE6D535C0824Q30763493-8E0431F9-8382-4AFC-B8CC-0BFED977E536Q30854643-48DE26D0-1FFD-4283-885F-B02C1339C3E4Q31075630-992C7148-266F-41F3-AB95-6C2BEDB90500Q33307453-FC54E217-43C7-4C1B-B325-4E750B1219AAQ33623561-3829C9CB-446C-42CE-9E8B-D8CC876ADD0CQ33996270-E38537A1-1C69-4C8F-B7E6-CFAC85A9C539Q34130881-BA88CF16-42EA-4896-9249-C069531678D6Q34359289-3C4C1BE6-8798-4A6D-8467-36B3AFEE7E14Q34363400-33575654-2687-4B38-90A8-8371DF67EAEDQ34575792-94D81B3F-F691-4BA1-9629-A41597F8FAA9Q35007777-5C4B229B-1D16-439A-B24D-D82F5E29155DQ35034555-FF084F0C-19D4-4F44-B98A-F630321015CCQ35040111-D9189BFD-D1ED-44AC-AE6A-777297840985Q35146930-A1D6343A-1E16-4E35-9AD1-A62E265B7C5EQ35584053-D0218E4B-840F-4728-BF1A-B9901ED22F8BQ35622059-4EC81463-A4EB-4EB7-8117-0ED76F266A90Q35799667-BF7F4700-FCA7-4391-8884-37322DE65683Q35945945-CC90CB26-031C-44AA-A108-06F969898156Q36055953-C6620109-371D-43D7-B76F-603505EEFBE8Q36088622-9AB43842-EF48-4B06-B997-94656167BCB4Q36095254-EC0D2274-FE88-40CC-A4DE-DF4ACB11119FQ36110190-CECF56F6-B783-452B-9345-8380ED2C1443Q36117673-157F1A80-DCE8-43BA-BD9E-A0E461FE3D64Q36470880-04DDB853-D477-42DB-A765-774D758758C3Q36816034-12EB8AE4-2EC4-4E88-8F4B-0111A74CBCEBQ37077422-E104CD04-FDC5-45EE-A437-E9A1339CC381Q37151102-31A39A42-99CB-4801-A0DD-2B4B12F352D6Q37214212-DC75D6BF-2D0C-4382-8D68-A3638AB376CBQ37304321-AC061476-A3F0-4EC7-8ECB-E29E6D4B13ADQ37345983-DA97B710-47A3-4CDF-974D-36DF4A7CE42EQ37383276-4A635F2A-EFB0-4D9A-9077-DB045549102BQ37661545-32FB2BFC-29D8-4AAA-8630-4EC2D528374AQ38024305-E6536BC0-A044-4A2C-A412-3A2FB8C030B6Q38081244-29A4FFBA-B0A7-4E9F-A2E5-C21734C27D3FQ38411366-0AEBC6F4-B9AF-4585-BAE8-93CAF4841752
P2860
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@ast
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@en
type
label
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@ast
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@en
prefLabel
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@ast
Prognostic role of a multigene ...... ing adjuvant systemic therapy.
@en
P2093
P1476
Prognostic role of a multigene ...... ving adjuvant systemic therapy
@en
P2093
Aysegul A Sahin
Drew Watson
Gabriel N Hortobagyi
Joffre Baker
Massimo Cristofanilli
Maureen Cronin
Michael Walker
Sang-Joon Lee
Steven Shak
P304
P356
10.1158/1078-0432.CCR-04-1707
P407
P577
2005-05-01T00:00:00Z